Steroid hormone-responsive secondary factor X deficiency.

disease and/or platelet activation, and may not participate directly in pathogenesis. We conclude that raised sP-selectin indicates a poor prognosis among patients with peripheral artery disease. The wide range of values means that this marker alone is unlikely to be of value in defining the risk of disease progression in any individual subject. However, it may be useful as part of a panel of markers that may include those suggestive of a pro-thrombotic capacity and endothelial cell dysfunction. If raised sP-selectin is truly a marker of platelet activation (8, 9), this may provide a new rationale for developing and using therapy aimed at the platelet. This preliminary finding may be applicable to other forms of atherosclerosis (e.g. stroke), and warrants further attention in larger groups of patients with more diverse disease(s).